GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was 1.39 GBP, up 123.2% from the year before. Over ten years it grew -4.3% a year on average. The highest annual figure on record is 3.66 GBP in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.39 GBP | +123.2% |
| FY2024 | Dec 31, 2024 | 0.62 GBP | -48.1% |
| FY2023 | Dec 31, 2023 | 1.20 GBP | -67.3% |
| FY2022 | Dec 31, 2022 | 3.66 GBP | +238.4% |
| FY2021 | Dec 31, 2021 | 1.08 GBP | -24.1% |
| FY2020 | Dec 31, 2020 | 1.43 GBP | +23.2% |
| FY2019 | Dec 31, 2019 | 1.16 GBP | +27.0% |
| FY2018 | Dec 31, 2018 | 0.91 GBP | +135.2% |
| FY2017 | Dec 31, 2017 | 0.39 GBP | +66.7% |
| FY2016 | Dec 31, 2016 | 0.23 GBP | -89.2% |
| FY2015 | Dec 31, 2015 | 2.15 GBP | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics